Affichage de 320 entreprises pour "Pharmaceuticals"
Entreprises
Sarepta Therapeutics is a global biotechnology company focused on precision genetic medicine for rare diseases. They engineer RNA platforms and gene therapy to transform genetic understanding into medicine. Sarepta strives to accelerate the development of new treatments, building the world's largest gene therapy manufacturing capacity.
Milestone Pharmaceuticals is a commercial-stage biopharmaceutical company focused on cardiovascular diseases. They are FDA-approved for treating acute episodes of PSVT with CARDAMYST™ and are developing etripamil for AFib-RVR. The company is dedicated to developing self-administered treatment solutions to improve the lives of people living with episodic cardiovascular conditions.
Shionogi is a pharmaceutical company focused on research and development to provide novel treatments, particularly for infectious diseases. They are committed to addressing antimicrobial resistance (AMR) and improving access to healthcare. Shionogi develops innovative therapies and promotes the proper use of medicines, striving to enhance affordability and accessibility worldwide.
Founded in 1968 by veterinarian Pierre-Richard Dick, Virbac provides a wide range of products and services to diagnose, prevent, and treat most animal pathologies. Present in over 100 countries, Virbac is a leading player in the veterinary medicine industry, focusing on improving the quality of life for animals. Key areas include companion and farm animals.
Septerna is a biotechnology company powered by its proprietary Native Complex Platform™ to develop oral small molecule therapies targeting GPCRs. The company focuses on treating patients in endocrinology, immunology and inflammation, and metabolic diseases, with a deep pipeline of product candidates.
INOVIO is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer, and infectious diseases. They are trailblazers in the DNA medicine field, working to commercialize innovative, next-generation medicines. Their focus is on innovating medicine to help save lives.
Corvus is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of immune diseases and cancer. Their lead program, soquelitinib, is a first-in-class, oral therapy that selectively inhibits ITK. The company focuses on advancing soquelitinib and collaborates to advance other clinical-stage programs. They are known for putting patients first and promptly reporting clinical data.
Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. They are studying investigational psilocybin treatment in treatment-resistant depression, post-traumatic stress disorder and anorexia nervosa. The company aims to connect science and compassion to reimagine mental health care.
BioCryst is a biotechnology company focused on discovering, developing, and commercializing novel medicines, particularly for rare diseases. They are world leaders in structure-guided drug design, focusing on oral small-molecule and protein therapeutics. The company is known for its commitment to delivering first-in-class or best-in-class treatments.
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. They focus on changing the narrative around viral skin diseases and making treatment more efficient. Their lead product, YCANTH®, is approved for the treatment of molluscum contagiosum. They are also developing VP-315 for the treatment of dermatologic oncologic conditions.
Editas Medicine is a pioneering gene editing company focused on developing transformative medicines using CRISPR/Cas9 and CRISPR/Cas12a genome editing systems. They aim to discover, develop, manufacture, and commercialize precise genomic medicines for a broad range of serious diseases worldwide. The company's pipeline includes experimental medicines focused on in vivo gene editing and other innovative approaches. Editas Medicine is headquartered in Cambridge, MA, with a site in Boulder, CO.
Galecto develops small molecules for the treatment of severe diseases, including cancer and fibrosis. The company focuses on modulators of galectin-3 and ENL/YEATS / FLT3 to treat cancer and severe liver diseases. Galecto has a unique therapeutic platform and aims to improve patient treatments.
Amylyx is a clinical-stage pharmaceutical company dedicated to developing novel therapies for diseases with high unmet needs. They focus on innovative treatments in neurodegenerative diseases and metabolic disorders. Key products include AMX0035 for ALS and avexitide for post-bariatric hypoglycemia (PBH). The company is committed to delivering with speed and rigor.
Crinetics Pharmaceuticals is a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine disease and endocrine-related tumors. Their mission is to build the world’s leading endocrine company that pioneers new therapeutics to help patients better control their disease and improve their daily lives. They focus on innovative molecules with a focus on the endocrine system and G-protein coupled receptors.
Akebia Therapeutics is a fully integrated biopharmaceutical company developing and commercializing unique therapeutics for people with kidney disease. With two FDA-approved products, they are a leader in the renal community. The company collaborates with medical professionals and patient organizations to better the lives of those affected by kidney disease.
Lifecore Biomedical is a CDMO (Contract Development and Manufacturing Organization) specializing in the development and manufacturing of injectable pharmaceuticals and medical devices. They offer expertise in formulation, aseptic filling, and packaging. With over 40 years of experience and international certifications, the company emphasizes its commitment to quality and compliance.
Rigel Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel treatments for immunological and oncological disorders. They develop small molecule drugs and biological products. The company has achieved approval for several products and has partnerships with major pharmaceutical companies.
Pharming is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. They are commercializing and developing a portfolio of innovative medicines to serve the unserved rare disease patient. Pharming aims to be a sustainable partner for all stakeholders and become a leading global rare disease company.
AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Their pipeline includes rosnilimab, a T cell depleter; ANB033, a CD122 antagonist; and ANB101, a BDCA2 modulator. They have out-licensed therapeutic antibodies, including a PD-1 antagonist to GSK and an IL-36R antagonist to Vanda Pharmaceuticals. AnaptysBio aims to separate its biopharma operations from its royalty assets by year-end 2026.
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. Leveraging their novel mRNA platform, they are committed to expanding the reach of cell therapy to patients. The company is dedicated to putting patients at the center of innovation, focused on bringing treatments for autoimmune disorders into the 21st century.